Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study

被引:11
作者
Welte, Thomas [1 ]
Arnold, Frederic [1 ,2 ]
Westermann, Lukas [1 ]
Rottmann, Felix A. [1 ]
Hug, Martin J. [3 ]
Neumann-Haefelin, Elke [1 ]
Ganner, Athina [1 ]
机构
[1] Univ Freiburg, Fac Med, Med Ctr, Dept Nephrol, Freiburg, Germany
[2] Univ Freiburg, Inst Microbiol & Hyg, Fac Med, Med Ctr, Freiburg, Germany
[3] Univ Freiburg, Fac Med, Med Ctr, Pharm, Freiburg, Germany
关键词
C3; glomerulopathy; glomerulonephritis; Dense deposit disease; Complement; Eculizumab; DENSE-DEPOSIT DISEASE; HEMOLYTIC-UREMIC SYNDROME; ALTERNATIVE PATHWAY; GLOMERULONEPHRITIS; COMPLEMENT; THERAPY; PATIENT; DYSFUNCTION; RITUXIMAB; DIALYSIS;
D O I
10.1186/s12882-023-03058-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background C3 Glomerulopathy (C3G) is a rare glomerular disease caused by dysregulation of the complement pathway. Based on its pathophysiology, treatment with the monoclonal antibody eculizumab targeting complement C5 may be a therapeutic option. Due to the rarity of the disease, observational data on the clinical response to eculizumab treatment is scarce.Methods Fourteen patients (8 female, 57%) treated for C3 glomerulopathy at the medical center of the University of Freiburg between 2013 and 2022 were included. Subjects underwent biopsy before enrollment. Histopathology, clinical data, and response to eculizumab treatment were analyzed. Key parameters to determine the primary outcome were changes of estimated glomerular filtration rate (eGFR) over time. Positive outcome was defined as > 30% increase, stable outcome as +/- 30%, negative outcome as decrease > 30% of eGFR.Results Eleven patients (78.8%) were treated with eculizumab, three received standard of care (SoC, 27.2%). Median follow-up time was 68 months (IQR: 45-98 months).Median eculizumab treatment duration was 10 months (IQR 5-46 months). After eculizumab treatment, five patients showed a stable outcome, six patients showed a negative outcome. Among patients receiving SoC, one patient showed a stable outcome, two patients showed a negative outcome.Conclusions The benefit of eculizumab in chronic progressive C3 glomerulopathy is limited.
引用
收藏
页数:9
相关论文
共 41 条
[21]   Clinical features and outcomes of 98 children and adults with dense deposit disease [J].
Lu, Der-Fa ;
Moon, Mikyung ;
Lanning, Lynne D. ;
McCarthy, Ann Marie ;
Smith, Richard J. H. .
PEDIATRIC NEPHROLOGY, 2012, 27 (05) :773-781
[22]   Spontaneous clinical improvement in dense deposit disease [J].
Marks, SD ;
Rees, L .
PEDIATRIC NEPHROLOGY, 2000, 14 (04) :322-324
[23]   Recurrent Dense Deposit Disease After Renal Transplantation: An Emerging Role for Complementary Therapies [J].
McCaughan, J. A. ;
O'Rourke, D. M. ;
Courtney, A. E. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 (04) :1046-1051
[24]   C3 Glomerulopathy: Clinicopathologic Features and Predictors of Outcome [J].
Medjeral-Thomas, Nicholas R. ;
O'Shaughnessy, Michelle M. ;
O'Regan, John A. ;
Traynor, Carol ;
Flanagan, Michael ;
Wong, Limy ;
Teoh, Chia Wei ;
Awan, Atif ;
Waldron, Mary ;
Cairns, Tom ;
O'Kelly, Patrick ;
Dorman, Anthony M. ;
Pickering, Matthew C. ;
Conlon, Peter J. ;
Cook, H. Terence .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2014, 9 (01) :46-53
[25]   Dense Deposit Disease: Clinicopathologic Study of 32 Pediatric and Adult Patients [J].
Nasr, Samih H. ;
Valeri, Anthony M. ;
Appel, Gerald B. ;
Sherwinter, Julius ;
Stokes, Michael B. ;
Said, Samar M. ;
Markowitz, Glen S. ;
D'Agati, Vivette D. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (01) :22-32
[26]   Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria [J].
Nykamp, Keith ;
Anderson, Michael ;
Powers, Martin ;
Garcia, John ;
Herrera, Blanca ;
Ho, Yuan-Yuan ;
Kobayashi, Yuya ;
Patil, Nila ;
Thusberg, Janita ;
Westbrook, Marjorie ;
Topper, Scott .
GENETICS IN MEDICINE, 2017, 19 (10) :1105-1117
[27]   Eculizumab in Pediatric Dense Deposit Disease [J].
Oosterveld, Michiel J. S. ;
Garrelfs, Mark R. ;
Hoppe, Bernd ;
Florquin, Sandrine ;
Roelofs, Joris J. T. H. ;
van den Heuvel, L. P. ;
Amann, Kerstin ;
Davin, Jean-Claude ;
Bouts, Antonia H. M. ;
Schriemer, Pietrik J. ;
Groothoff, Jaap W. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2015, 10 (10) :1773-1782
[28]   Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy [J].
Ozkaya, Ozan ;
Nalcacioglu, Hulya ;
Tekcan, Demet ;
Genc, Gurkan ;
Meydan, Bilge Can ;
Ozdemir, B. Handan ;
Baysal, M. Kemal ;
Keceligil, Hasan Tahsin .
PEDIATRIC NEPHROLOGY, 2014, 29 (07) :1283-1287
[29]   Prevention of C5 activation ameliorates spontaneous and experimental factor H-deficient glomerulonephritis in mice [J].
Pickering, M. C. ;
Warren, J. ;
Rose, K. L. ;
Carlucci, F. ;
Wang, Y. ;
Walport, M. J. ;
Cook, H. T. ;
Botto, M. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (25) :9649-9654
[30]   Complement and glomerular disease: new insights [J].
Pickering, Matthew ;
Cook, H. Terence .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2011, 20 (03) :271-277